Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

WARREN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful...
November 05, 2025 16:01 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term...
November 04, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company’s ongoing development initiatives Matthew...
November 03, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler

WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
October 30, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting

WARREN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
October 27, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
October 08, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe...
September 04, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive...
August 26, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
August 14, 2025 06:28 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...